Milestone Pharmaceuticals Inc
MIST
Company Profile
Business description
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Contact
1111 Dr. Frederik-Phillips Boulevard
Suite 420
MontrealQCH4M 2X6
CANT: +1 514 336-0444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
Big 4 earnings: Morningstar analysts form view on impact of slowing housing market
Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player
stocks
ASX healthcare share remains cheap despite mixed earnings result
Shares in Aussie listed healthcare name undervalued post earnings.
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,391.10 | 14.40 | -0.15% |
| CAC 40 | 8,714.94 | 11.09 | -0.13% |
| DAX 40 | 26,391.42 | 67.54 | 0.26% |
| Dow JONES (US) | 53,791.85 | 184.13 | -0.34% |
| FTSE 100 | 10,844.19 | 18.31 | -0.17% |
| HKSE | 25,362.91 | 289.91 | -1.13% |
| NASDAQ | 26,445.45 | 159.91 | -0.60% |
| Nikkei 225 | 67,040.18 | 69.96 | 0.10% |
| NZX 50 Index | 13,779.05 | 81.61 | -0.59% |
| S&P 500 | 7,728.20 | 24.91 | -0.32% |
| S&P/ASX 200 | 9,193.00 | 18.60 | -0.20% |
| SSE Composite Index | 3,943.00 | 8.90 | 0.23% |